EUVIMEDEUVIMED entdecken
Multizentrische Studie

Proliferation-Guided Risk Stratification in HER2-Low versus HER2-Positive Hormone Receptor-Positive Breast Cancer: A Multicenter Retrospective Analysis

Sait Kitapli, Özgür Tanrıverdi, İsmail Bayrakci, Taliha Guclu, Bilgin Demir, Gokhan Colak, Ali Alkan, Merve Turan, Esin Oktay, Gamze Gokoz Dogu, Sernaz Uzunoglu, Sabri Barutca

Oncology Research and Treatment · 2026

DOI: 10.1159/000550484 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Oncology Research and Treatment, 2026. Verfasst von Sait Kitapli und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Mugla Sitki Kocman University Faculty of Medicine, Mugla, Turkey. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms, Ki-67 Antigen, Biomarkers, Tumor. Die Arbeit nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

HER2-low breast cancer is a newly characterized subgroup with unclear prognostic implications. This study investigates the prognostic role of Ki67 in hormone receptor-positive (HR+) HER2-low and HER2-positive breast cancer.

Methods

We retrospectively analyzed 224 HR+ breast cancer patients from four tertiary centers (96 HER2-low, 128 HER2-positive). Patients were stratified into stages 1–3 (n = 156) and stage 4 (n = 68). Survival outcomes were assessed according to HER2 and Ki67 status using Kaplan-Meier analysis and Cox regression.

Results

HER2-low patients were older (≥65 years: 65% vs. 28%, p < 0.001). In stage 1–3 patients, disease-free survival (DFS) was significantly longer in the HER2-low subgroup (median: 86 vs. 59 months; p < 0.001) and in those with Ki67 < 20% (median: 74 vs. 34 months; p < 0.001). Multivariable analysis confirmed high Ki67 (HR: 1.664; 95% CI: 1.564–2.048; p < 0.001), hormone receptor negativity (HR: 1.967; 95% CI: 1.614–2.433; p = 0.020), larger tumor size, and axillary nodal involvement as independent predictors of poor DFS. Among stage 4 patients, overall survival (OS) did not differ significantly by HER2 status (34 vs. 28 months; p = 0.427) but was significantly shorter in those with Ki67 ≥ 20% (18 vs. 29 months; p < 0.001). In multivariable analysis, high Ki67 (HR: 2.174; 95% CI: 1.994–2.256; p < 0.001), hormone receptor negativity (HR: 1.649; 95% CI: 1.184–2.143; p < 0.001), and presence of brain metastasis (HR: 1.564; 95% CI: 1.379–1.994; p < 0.001) were independent predictors of poor OS.

Conclusion

Ki67 appears to be an important prognostic biomarker in HR+ breast cancer across both HER2-low and HER2-positive subgroups. Dual stratification by HER2 and Ki67 status may improve risk assessment and help identify high-risk subgroups who could benefit from treatment approaches beyond endocrine therapy alone. These findings warrant confirmation in prospective studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesBreast NeoplasmsKi-67 AntigenBiomarkers, TumorReceptors, EstrogenReceptors, ProgesteroneHumansFemaleRetrospective StudiesPrognosisAgedMiddle AgedDisease-Free SurvivalNeoplasm StagingRisk AssessmentAdultCell ProliferationAged, 80 and over

Stichwörter der Autor:innen

Breast cancerHER2-low breast cancerHormone receptor-positive diseaseKi67PrognosisProliferationSurvivalTargeted therapy

Substanzen

Erb-b2 Receptor Tyrosine KinasesKi-67 AntigenERBB2 protein, humanBiomarkers, TumorReceptors, EstrogenReceptors, Progesterone

Autor:innen und Institutionen

  • Department of Medical Oncology, Mugla Sitki Kocman University Faculty of Medicine, Mugla, Turkey.
  • Department of Medical Oncology, Mugla Sitki Kocman University Faculty of Medicine, Mugla, Turkey, ozgurtanriverdi@mu.edu.tr.
  • Department of Medical Oncology, Trakya University Faculty of Medicine, Edirne, Turkey.
  • Department of Medical Oncology, Pamukkale University Faculty of Medicine, Denizli, Turkey.
  • Department of Medical Oncology, Adnan Mendres University Faculty of Medicine, Aydin, Turkey.

Zitieren

APA

Kitapli, S., Tanrıverdi, Ö., Bayrakci, İ., Guclu, T., Demir, B., Colak, G., Alkan, A., Turan, M., Oktay, E., Gokoz Dogu, G., Uzunoglu, S., & Barutca, S. (2026). Proliferation-Guided Risk Stratification in HER2-Low versus HER2-Positive Hormone Receptor-Positive Breast Cancer: A Multicenter Retrospective Analysis. Oncology Research and Treatment. https://doi.org/10.1159/000550484

Vancouver

Kitapli S, Tanrıverdi Ö, Bayrakci İ, Guclu T, Demir B, Colak G, et al. Proliferation-Guided Risk Stratification in HER2-Low versus HER2-Positive Hormone Receptor-Positive Breast Cancer: A Multicenter Retrospective Analysis. Oncology Research and Treatment. 2026. doi:10.1159/000550484

BibTeX
@article{Kitapli2026,
  author = {Kitapli, Sait and Tanrıverdi, Özgür and Bayrakci, İsmail and Guclu, Taliha and Demir, Bilgin and Colak, Gokhan and Alkan, Ali and Turan, Merve and Oktay, Esin and Gokoz Dogu, Gamze and Uzunoglu, Sernaz and Barutca, Sabri},
  title = {Proliferation-Guided Risk Stratification in HER2-Low versus HER2-Positive Hormone Receptor-Positive Breast Cancer: A Multicenter Retrospective Analysis},
  journal = {Oncology Research and Treatment},
  year = {2026},
  doi = {10.1159/000550484}
}
Kostenlos starten →